
Article 1 
Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.
Article 2 
By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).
Article 3 

1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
2. Article 1 shall apply in respect of substances and mixtures from 1 January 2017.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 24 July 2015.
For the Commission
The President
Jean-Claude JUNCKER
ANNEX

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

((1)) Table 3.1 is amended as follows:

((a)) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
007-004-00-1 nitric acid … % 231-714-2 7697-37-2 Ox. Liq. 2Skin Corr. 1A H272H314 GHS03GHS05Dgr H272H314 EUH071 Skin Corr. 1A; H314: C ≥ 20 %Skin Corr. 1B; H314: 5 % ≤ C < 20 %Ox. Liq. 2; H272: C ≥ 99 %Ox. Liq. 3; H272: 99 % > C ≥ 65 % B
015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 Water-react. 1Acute Tox. 2Acute Tox. 3Acute Tox. 1Eye Dam. 1Aquatic Acute 1 H260H300H311H330H318H400 GHS02GHS06GHS05GHS09Dgr H260H300H311H330H318H400 EUH029EUH032 M = 100 
031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. 1BCarc. 1BSTOT RE 1 H360FH350H372 (respiratory and haematopoietic systems) GHS08Dgr H360FH350H372 (respiratory and haematopoietic systems)   
050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. 1BAcute Tox. 3Acute Tox. 4*STOT RE 1Skin Irrit. 2Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 H360FDH301H312H372**H315H319H400H410 GHS08GHS06GHS09Dgr H360FDH301H312H372**H315H319H410  *STOT RE 1; H372: C ≥ 1 %STOT RE 2; H373: 0,25 % ≤ C < 1 %Skin Irrit. 2; H315:C ≥ 1 %Eye Irrit. 2; H319:C ≥ 1 %M = 10 A1
603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 Flam. Liq. 2Carc. 2Acute Tox. 4*Acute Tox. 4*Acute Tox. 4*STOT SE 3Skin Irrit. 2Eye Irrit. 2 H225H351H302H312H332H335H315H319 GHS02GHS08GHS07Dgr H225H351H302H312H332H335H315H319   
603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. 2Acute Tox. 4Aquatic Acute 1Aquatic Chronic 1 H361d***H302H400H410 GHS08GHS07GHS09Wng H361d***H302H410  M = 1M = 10 
606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone — 141112-29-0 Repr. 2Aquatic Acute 1Aquatic Chronic 1 H361d***H400H410 GHS08GHS09Wng H361d***H410  M = 10M = 100 
607-197-00-8 nonanoic acid 203-931-2 112-05-0 Skin Irrit. 2Eye Irrit. 2Aquatic Chronic 3 H315H319H412 GHS07Wng H315H319H412   
613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 252-615-0 35554-44-0 Carc. 2Acute Tox. 3Acute Tox. 4Eye Dam. 1Aquatic Chronic 1 H351H301H332H318H410 GHS08GHS06GHS05GHS09Dgr H351H301H332H318H410  M = 10 
613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. 2STOT RE 2Skin Corr. 1CSkin Sens. 1AAquatic Acute 1Aquatic Chronic 1 H361dH373 (liver)H314H317H400H410 GHS08GHS05GHS07GHS09Dgr H361dH373 (liver)H314H317H410 EUH071 M = 1M = 1 
613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. 2Acute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H351H302H317H400H410 GHS08GHS07GHS09Wng H351H302H317H410  M = 1M = 1 
613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 Acute Tox. 3Acute Tox. 3Aquatic Acute 1Aquatic Chronic 1 H331H301H400H410 GHS06GHS09Dgr H331H301H410  M = 1 000M = 1 000 
((b)) the following entries are inserted in accordance with the order of the entries set out in Table 3.1:

Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Eye Irrit. 2 H319 GSH07Wng H319   
604-092-00-9 phenol, dodecyl-, branched [1];phenol, 2-dodecyl-, branched;phenol, 3-dodecyl-, branched;phenol, 4-dodecyl-, branched;phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1] 121158-58-5 [1]74499-35-7 [2] Skin Corr. 1CAquatic Acute 1Aquatic Chronic 1 H314H400H410 GHS05GHS09Dgr H314H410  M = 10M = 10 
606-148-00-8 carvone (ISO);2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1]218-827-2 [2]229-352-5 [3] 99-49-0 [1]2244-16-8 [2]6485-40-1 [3] Skin Sens. 1 H317 GHS07Wng H317   
606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione — 335104-84-2 Repr. 2STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H361dH373 (eyes, kidneys, liver)H317H400H410 GHS08GHS07GHS09Wng H361dH373 (eyes, kidneys, liver)H317H410  M = 100M = 10 
607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H373 (kidneys)H317H400H410 GHS08GHS07GHS09Wng H373 (kidneys)H317H410  M = 1M = 1 
607-708-00-4 octanoic acid 204-677-5 124-07-2 Skin Corr. 1CAquatic Chronic 3 H314H412 GHS05Dgr H314H412   
607-709-00-X decanoic acid 206-376-4 334-48-5 Skin Irrit. 2Eye Irrit. 2Aquatic Chronic 3 H315H319H412 GHS07Wng H315H319H412   
607-710-00-5 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. 1B H360FD GHS08Dgr H360FD   
607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. 2STOT SE 3Eye Irrit. 2Skin Sens. 1AAquatic Acute 1Aquatic Chronic 1 H361fdH335H319H317H400H410 GHS08GHS07GHS09Wng H361fdH335H319H317H410  M = 1M = 1 
607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. 2STOT RE 2Skin Corr. 1CSkin Sens. 1AAquatic Chronic 1 H361dH373 (liver)H314H317H410 GHS08GHS05GHS07GHS09Dgr H361dH373 (liver)H314H317H410 EUH071 M = 1 
607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 Acute Tox. 3Acute Tox. 2Skin Sens. 1BAquatic Acute 1Aquatic Chronic 1 H301H330H317H400H410 GHS06 GHS09Dgr H301H330H317H410  M = 100M = 1 000 
607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. 2Aquatic Acute 1Aquatic Chronic 1 H351H400H410 GHS08GHS09Wng H351H410  M = 100M = 10 
607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H373H317H400H410 GHS08GHS07GHS09Wng H373H317H410  M = 1M = 1 
613-319-00-0 imidazole 206-019-2 288-32-4 Repr. 1BAcute Tox. 4Skin Corr. 1C H360DH302H314 GHS08GHS07GHS05Dgr H360DH302H314   
613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. 2Aquatic Acute 1Aquatic Chronic 1 H351H400H410 GHS08GHS09Wng H351H410  M = 10M = 10 
616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1M = 1 
616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. 2STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H351H373 (eyes, kidneys)H400H410 GHS08GHS09Wng H351H373 (eyes, kidneys)H410  M = 1 000M = 100 
616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Acute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H302H317H400H410 GHS07GHS09Wng H302H317H410  M = 10M = 10 
616-216-00-9 flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Acute Tox. 4 H302 GHS07Wng H302   
616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Acute Tox. 4Aquatic Acute 1Aquatic Chronic 1 H302H400H410 GHS07GHS09Wng H302H410  M = 1M = 1 
((2)) Table 3.2 is amended as follows:

((a)) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
007-004-00-1 nitric acid … % 231-714-2 7697-37-2 O; R8C; R35 O; CR: 8-35S: (1/2-)26-28- 36/37/39-45-63 O; R8: C ≥ 65 %C; R35: C ≥ 20 %C; R34: 5 % ≤ C < 20 % B
015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 F; R15/29T+; R26/28Xn; R21R32Xi; R38-41N; R50 F; T+; NR: 15/29-21-26/28-32-38-41-50S:(1/2-)26-28-30-36/37/39-43-45-60-61 N; R50: C ≥ 0,25 % 
031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. Cat. 2; R60Carc. Cat. 2; R45T; R48/23 TR: 45-48/23-60S: 45-53  E
050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. Cat. 2; R60-61T; R25-48/23/25Xn; R21Xi; R36/38N; R50-53 T; NR: 21-25-36/38-48/23/25-50/53-60-61S: 45-53-60-61 T; R25: C ≥ 2,5 %Xn; R22: 0,25 % ≤ C < 2,5 %Xn: R21: C ≥ 1 %T; R48/23/25: C ≥ 1 %Xn; R48/20/22: 0,25 % ≤ C < 1 %Xi; R36/38: C ≥ 1 %N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % A1
603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 F; R11Carc. Cat. 3; R40Xn; R20/21/22Xi; R36/37/38 F; XnR: 11-20/21/22-36/37/38-40-S: (2-)9-16-29-36/37-46  
603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. Cat. 3; R63Xn; R22N; R50-53 Xn; NR: 22-50/53-63S: (2-)22-36/37-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C <25 %R52-53: 0,25 % ≤ C < 2,5 % 
606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone — 141112-29-0 Repr. Cat. 3; R63N; R50-53 Xn; NR: 50/53-63S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
607-197-00-8 nonanoic acid 203-931-2 112-05-0 Xi; R36/38N; R51-53 Xi; NR: 36/38-51/53S: (2-)46-61  
613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 252-615-0 35554-44-0 Carc. Cat. 3; R40Xn; R20/22Xi; R41N; R51-53 Xn; NR: 20/22-40-41-51/53S: (2-)26-36/37/39-46-61  
613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. Cat. 3; R63C; R34R43N; R50-53 C; NR: 34-43-50/53-63S: (1/2-)26-28-36/37/39-45-60-61 C; R34: C ≥ 10 %Xi; R36/37/38: 5 % ≤ C < 10 %N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. Cat. 3; R40Xn; R22R43N; R50-53 Xn; NR: 22-40-43-50/53S: (2-)36/37-46-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 T; R23/25N; R50-53 T; NR: 23/25-50/53S: (1/2-)36/37-45-60-61 N; R50-53: C ≥ 0,025 %N; R51-53: 0,0025 % ≤ C < 0,025 %R52-53: 0,00025 % ≤ C < 0,0025 % 
((b)) the following entries are inserted in accordance with the order of the entries set out in Table 3.2:

Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Xi; R36 XiR: 36S: (2-)25-46  
604-092-00-9 phenol, dodecyl-, branched [1];phenol, 2-dodecyl-, branched;phenol, 3-dodecyl-, branched;phenol, 4-dodecyl-, branched;phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1]-[2] 121158-58-5 [1]74499-35-7 [2] C; R34N; R50-53 C; NR: 34-50/53S: (1/2-)26-36/37/39-45-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
606-148-00-8 carvone (ISO);2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1]218-827-2 [2]229-352-5 [3] 99-49-0 [1]2244-16-8 [2]6485-40-1 [3] R43 XiR: 43S: (2-)24-37  
606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione  335104-84-2 Repr. Cat. 3; R63Xn; R48/22R43N; R50-53 Xn; NR: 43-48/22-50/53-63S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % 
607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 Xn; R48/22R43N; R50-53 Xn; NR: 43-48/22-50/53S: (2-)24-37-46-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
607-708-00-4 octanoic acid 204-677-5 124-07-2 C; R34N; R51-53 C; NR: 34-51/53S: (1/2-)26-36/37/39-45-61  
607-709-00-X decanoic acid 206-376-4 334-48-5 Xi; R36/38N; R51-53 Xi; NR: 36/38-51/53S: (2-)25-46-61  
607-710-00-5 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. Cat. 2; R60-61 TR: 60-61S: 53-45  
607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. Cat. 3; R62-63Xi; R36/37R43N; R50-53 Xn; NR: 36/37-43-50/53-62-63S: (2-)36/37-60-61 Xi; R43: C ≥ 0,1 %N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. Cat. 3; R63C; R34R43N; R51-53 C; NR: 34-43-51/53-63S: (1/2-)26-28-36/37/39-45-61 C; R34: C ≥ 10 %Xi: R36/37/38: 5 % ≤ C < 10 % 
607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 T+; R26Xn; R22R43N; R50-53 T+; NR: 22-26-43-50/53S: (1/2-)28-36/37-45-60-61-63 N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % 
607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. Cat. 3; R40N; R50-53 Xn; NR: 40-50/53S: (2-)36/37-60-61 N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % 
607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 R43N; R50-53 Xi; NR: 43-50/53S: (2-)24-37-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
613-319-00-0 imidazole 206-019-2 288-32-4 Repr. Cat 2; R61Xn; R22C; R34 T; CR: 22-34-61S: 53-45  
613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. Cat. 3; R40N; R50-53 Xn; NR: 40-50/53S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 N; R50-53 NR: 50/53S: 60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C <25 %R52-53: 0,25 % ≤ C < 2,5 % 
616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. Cat. 3; R40Xn; R48/22N; R50-53 Xn; NR: 40-48/22-50/53S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,025 %N; R51-53: 0,0025 % ≤ C < 0,025 %R52/53: 0,00025 % ≤ C < 0,0025 % 
616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Xn; R22R43N; R50-53 Xn; NR: 22-43-50/53S: (2-)24-37-60-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
616-216-00-9 flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Xn; R22 XnR: 22S: (2-)46  
616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Xn; R22N; R50-53 Xn; NR: 22-50/53S: (2-)60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
